http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102036867-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
filingDate | 2018-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2019-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2019-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-102036867-B1 |
titleOfInvention | Biomarker composition for diagnosing anticancer drug resistance of ovarian cancer patients comprising ARD1 |
abstract | The present invention relates to a biomarker composition for diagnosing anticancer drug resistance in an ovarian cancer patient including ARD1 (Arrest-defective 1 protein) as an active ingredient, and to the use of ARD1 as a cancer stem cell control target using the same. It was confirmed that ARD1 expression is increased while acquiring stem cell function. Analysis of ARD1 expression level predicts resistance to anticancer drug treatment of ovarian cancer patients, and at the same time, it is possible to search for cancer stem cell distribution in cancer tissues. It is expected to be useful for determining the anticancer drug treatment direction of ovarian cancer. |
priorityDate | 2018-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 129.